Protective effects of epigallocatechin gallate (EGCG) on endometrial, breast, and ovarian cancers

Yun Ju Huang, Kai Lee Wang, Hsin Yuan Chen, Yi Fen Chiang, Shih Min Hsia

Research output: Contribution to journalReview articlepeer-review

42 Citations (Scopus)


Green tea and its major bioactive component, (−)-epigallocatechin gallate (EGCG), possess diverse biological properties, particularly antiproliferation, antimetastasis, and apoptosis induction. Many studies have widely investigated the anticancer and synergistic effects of EGCG due to the side effects of conventional cytotoxic agents. This review summarizes recent knowledge of underlying mechanisms of EGCG on protective roles for endometrial, breast, and ovarian cancers based on both in vitro and in vivo animal studies. EGCG has the ability to regulate many pathways, including the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), inhibition of nuclear factor-κB (NF-κB), and protection against epithelial–mesenchymal transition (EMT). EGCG has also been found to interact with DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), which affect epigenetic modifications. Finally, the action of EGCG may exert a suppressive effect on gynecological cancers and have beneficial effects on auxiliary therapies for known drugs. Thus, future clinical intervention studies with EGCG will be necessary to more and clear evidence for the benefit to these cancers.

Original languageEnglish
Article number1481
Pages (from-to)1-19
Number of pages19
Issue number11
Publication statusPublished - Nov 2020


  • Breast cancer
  • Endometrial cancer
  • Epigallocatechin gallate
  • Ovarian cancer
  • Synergistic effect

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Protective effects of epigallocatechin gallate (EGCG) on endometrial, breast, and ovarian cancers'. Together they form a unique fingerprint.

Cite this